Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib with Radiation and/or Temozolomide in Glioblastoma
NCT03150862Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of pamiparib in glioblastoma (GBM), sponsored by BeiGene. Started Jul 2017; status: completed.
02
Drugs
pamiparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03150862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150862.